Laval, Canada
Liminal BioSciences is a development-stage biopharmaceutical company distinguished by its focus on novel small molecule therapeutics that target G protein-coupled receptor (GPCR) pathways. With an eye on creating best-in-class solutions, the company aims to address unmet needs in metabolic, inflammatory, and fibrotic diseases. Operating since 1992, it leverages its integrated drug discovery platform and expertise in medicinal chemistry across hubs in Canada and the UK.
In its pursuit of innovation, the company recently attracted a $2.40M post-IPO equity investment on 16 July 2020 backed by Amorchem and Genesys Partners. Despite its lengthy operational tenure, the company functions within strategic sectors—Biotechnology and Health Care—poised for growth, particularly as the demand for unique therapeutic solutions intensifies. Liminal BioSciences presents an opportunity for investors eager to drive advancements in the GPCR landscapes.
